CS MEDICA A/S Secures Repurchase Orders from Key European Partners
CANNORDIC Continues Momentum with Recurring Orders of 45.000 Units from European Healthcare Leaders
CS MEDICA, a pioneering MedTech company specializing in pain management and autoimmune diseases with innovative substance-based medical devices containing bioactive CBD, announces that its subsidiary, CANNORDIC, has received repurchase orders for 45,000 units from its German partner, Alsitan, and Spanish partner, Uriach, for delivery in Q3 and Q4, 2024.
CANNORDIC hereby strengthens its market penetration with a total of 241,000 units in orders from the two leading European Healthcare Partners, with Alsitan placing its sixth order and Uriach placing its third order.
It marks a significant step in reinforcing CANNORDIC's presence in the global market for innovative substance-based medical devices with bioactive CBD aimed at pain relief and autoimmune diseases.
These recurring orders reflect our partners' trust in our products and underscore their success in local markets, supporting our continued growth in the healthcare sector, says Lone Henriksen, CEO of CS MEDICA.
For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/
CS MEDICA A/S, a Danish MedTech pioneer, specializes in developing evidence-based, CBD-integrated treatments for pain management, autoimmune and stress-related disorders. With a focus on patient-centric care, our products range from innovative R&D to registered over-the-counter substance-based medical devices and dermaceuticals. Our flagship CANNASEN® brand, alongside our own-label solutions, exemplifies our dedication to safe, high-quality treatments for both human and veterinary health globally.
The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com and LinkedIn.
CANNORDIC A/S, a subsidiary of CS MEDICA Group, is a pioneering MedTech company specializing in innovative substance-based medical devices containing bioactive CBD. Our dedication to enhancing lives by integrating innovation, science, technology, and natural cannabis compounds positions it as a pioneer in the medical technology industry. The company ensures robust research, development, manufacturing, compliance, data insights, and commercialization processes.